Itovebi, approved for some patients with breast cancer, is the first PI3K inhibitor to display a survival benefit, according ...

BridgeBio Oncology Therapeutics, a company working to advance the field of therapies addressing a validated but elusive group of cancer targets, has reached a deal to go public in a SPAC merger ...

In addition, the PI3K pathway is stimulated as a physiological ... These include mammalian target of rapamycin (mTOR) inhibitors of the 'rapalog' family of rapamycin analogues, ether lipids ...